Vir Biotechnology (VIR) Equity Ratio (2018 - 2026)

Vir Biotechnology's Equity Ratio history runs 9 years deep, the most recent figure standing at 0.79 for Q1 2026.

• In Q1 2026, Equity Ratio fell 0.71% year-over-year to 0.79; the TTM figure through Mar 2026 stood at 0.79 (down 0.71% YoY), while the FY2025 annual figure was 0.76, down 7.21% from the prior year.
• Equity Ratio came in at 0.79 for Q1 2026 at Vir Biotechnology, up from 0.76 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q1 2024 to a low of 0.69 in Q1 2022.
• A 5-year average of 0.79 and a median of 0.8 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio rose 20.91% in 2022 and decreased 7.48% in 2025, its largest moves.
• Vir Biotechnology's Equity Ratio stood at 0.74 in 2022, then rose by 11.74% to 0.83 in 2023, then slipped by 0.75% to 0.82 in 2024, then decreased by 7.21% to 0.76 in 2025, then gained by 3.85% to 0.79 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.79, 0.76, and 0.78 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison